Checkpoint Therapeutics' (CKPT) "Buy" Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT - Free Report) in a research note published on Monday,Benzinga reports. They currently have a $4.80 price objective on the stock.

Other analysts have also issued reports about the company. Lake Street Capital restated a "hold" rating and issued a $4.10 price target (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. HC Wainwright restated a "neutral" rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th.

Checkpoint Therapeutics Stock Performance

CKPT stock traded down $0.04 during mid-day trading on Monday, hitting $4.01. 1,109,193 shares of the company were exchanged, compared to its average volume of 1,144,691. Checkpoint Therapeutics has a 1-year low of $1.38 and a 1-year high of $4.50. The firm's 50 day simple moving average is $3.40 and its 200 day simple moving average is $3.30. The firm has a market cap of $195.58 million, a P/E ratio of -2.17 and a beta of 1.21.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47). The company had revenue of $0.04 million for the quarter. On average, equities research analysts predict that Checkpoint Therapeutics will post -0.94 EPS for the current fiscal year.

Remove Ads

Insider Buying and Selling at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 15,090 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $4.04, for a total value of $60,963.60. Following the completion of the sale, the chief executive officer now directly owns 3,759,929 shares in the company, valued at approximately $15,190,113.16. This trade represents a 0.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO William Garrett Gray sold 12,322 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the completion of the sale, the chief financial officer now owns 1,446,322 shares in the company, valued at $5,857,604.10. This represents a 0.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 121,086 shares of company stock worth $446,879 over the last ninety days. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CKPT. Ameriflex Group Inc. acquired a new stake in shares of Checkpoint Therapeutics during the 4th quarter worth about $32,000. PUREfi Wealth LLC bought a new position in Checkpoint Therapeutics in the 4th quarter valued at about $32,000. SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics during the fourth quarter worth approximately $32,000. Stifel Financial Corp bought a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth approximately $32,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Checkpoint Therapeutics by 157.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock valued at $34,000 after purchasing an additional 6,486 shares during the last quarter. 22.00% of the stock is owned by institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.